Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: A randomized controlled double-blind clinical trial

Journal of Sichuan University (Medical Science)

Volumn 36, Issue 2, 2005, Pages 267-270

  Li, Jian Wei ^a   Tian, Hao Ming ^a   Yu, Hong Lin ^a   Zhang, Xiang Xun ^a   Zhao, Gui Zhi ^a   Wang, Jia Nan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Nateglinide; Randomized controlled double blind clinical trial; Repaglinide; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NATEGLINIDE; REPAGLINIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

EID: 16244386544     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care, 2003;26 (3):881.
2. Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes, 1999;48(1):99.
3. Hu S, Wang S, Fanelli B, et al. Pancreatic β-cell KATP channel activity and membrane binding studies with nateglinide, a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther, 2000;293(2):444.
4. Kalbag JB, Walter YH, Nedelman JR, et al. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care, 2001;24(1):73.
5. Hansen AM, Christensen IT, Hansen JB, et al. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes, 2002;51(9):2789.
6. Kahn SE, Montgomery B, Howell WM, et al. Nateglinide increases first phase insulin secretion and enhances glucose clearance in type 2 diabetes. Diabetes, 2000;49 (Suppl 1): A113.
7. Kahn SE, Montgomery B, Howell W, et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab, 2001;86(12):5824.
8. Raskin P, Klaff L, McGill J, et al. Repaglinide vs. Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care, 2003;26(7): 2063.
9. Rosenstock J, Shen SG, Gattin MR, et al. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care, 2002;25 (9):1529.
10. Buse JB, Tan MH, Prince MJ, et al. The effects of oral antihyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab, 2004;6(2):133.